The round was led by Israel Biotech Fund with participation from new investors, The Phoenix Insurance Company and Migdal Insurance Company, two of Israel’s leading institutional investors, and Biotel, as well as existing investors including Arkin Bio Ventures and Primera Capital.
Biosight Closes $46M Series C Financing to Advance Clinical Oncology Programs
